Pfizer Inc. (NYSE:PFE) Shares Sold by IHT Wealth Management LLC

IHT Wealth Management LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,380 shares of the biopharmaceutical company's stock after selling 19,359 shares during the quarter. IHT Wealth Management LLC's holdings in Pfizer were worth $4,255,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the 4th quarter valued at $31,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 0.7 %

Shares of NYSE PFE traded down $0.15 during trading on Wednesday, reaching $22.38. The stock had a trading volume of 50,748,501 shares, compared to its average volume of 40,559,569. The business's 50-day moving average price is $24.69 and its 200-day moving average price is $26.06. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market cap of $126.93 billion, a P/E ratio of 15.87, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business posted $0.10 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.69%. Pfizer's dividend payout ratio (DPR) is presently 121.99%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PFE shares. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday. They set a "neutral" rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.